Trial of Psilocybin versus Escitalopram for Depression

In a randomized trial involving 59 selected patients with depression, the change in depression scale scores from baseline to week 6 did not differ significantly between patients who received two doses of psilocybin and those who received daily escitalopram. Secondary outcomes generally favored psilo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-04, Vol.384 (15), p.1402-1411
Hauptverfasser:	Carhart-Harris, Robin, Giribaldi, Bruna, Watts, Rosalind, Baker-Jones, Michelle, Murphy-Beiner, Ashleigh, Murphy, Roberta, Martell, Jonny, Blemings, Allan, Erritzoe, David, Nutt, David J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Antidepressants Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use Antidepressive Agents, Second-Generation - adverse effects Antidepressive Agents, Second-Generation - therapeutic use Citalopram Citalopram - adverse effects Citalopram - therapeutic use Clinical trials Depressive Disorder, Major - drug therapy Depressive Disorder, Major - psychology Double-Blind Method Drug dosages Female Hallucinogens - adverse effects Hallucinogens - therapeutic use Humans Magnetic resonance imaging Male Medical personnel Medical research Mental depression Mental health Middle Aged Patients Placebos Psilocybin Psilocybin - adverse effects Psilocybin - therapeutic use Psychedelic drugs Psychotherapy Recruitment Regulatory agencies Remission Self Report Serotonin Surveys and Questionnaires Video teleconferencing Websites Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized trial involving 59 selected patients with depression, the change in depression scale scores from baseline to week 6 did not differ significantly between patients who received two doses of psilocybin and those who received daily escitalopram. Secondary outcomes generally favored psilocybin over escitalopram.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2032994